Sugar cookies sold at Target in 20 states recalled over fears of wood chip contamination
More than 800 cases of Favorite Day Bakery Frosted Sugar Cookies were recalled by the retailer on July 22.
The cookies, which come in a 10-count box, were sold to stores in Washington D.C., and the following states:
Connecticut
Delaware
Illinois
Indiana
Kentucky
Massachusetts
Maryland
Maine
Michigan
Missouri
North Carolina
New Jersey
New York
Ohio
Pennsylvania
Rhode Island
Tennessee
Virginia
Vermont
The Food and Drug Administration classified the recall as Class II, which means the product 'may cause temporary or medically reversible adverse health consequences.'
The Independent has reached out to Target for comment.
Target has also recently recalled other grocery products, including the High Noon Vodka Seltzer Beach 12-Pack.
The alcoholic seltzers were recalled on July 29 after it was found that some of the variety packs contained Celsius Astro Vibe energy drink cans that were accidentally filled with vodka seltzer.
At the time of the recall, there were no reported illnesses or adverse events from the products.
A representative for High Noon previously told The Independent: 'We are working with the FDA, retailers and distributors to proactively manage the recall to ensure the safety and well-being of our consumers. The states that may be impacted are: Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin.'
Over 300,000 kitchen step stools sold at stores, including Target, Walmart and Home Depot, were also recently recalled due to safety concerns.
The Cosco 2-Step Kitchen Stepper was recalled on July 31 after 34 reports of the stool's safety bar detaching or breaking, including two incidents that resulted in head injuries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
US FDA approves Insmed's drug as first treatment for a chronic lung disease
Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed's (INSM.O), opens new tab oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. Shares of the New Jersey-based drugmaker rose 6% in morning trade. Insmed's drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production. The condition affects 350,000 to 500,000 adults in the U.S., according to the American Lung Association. Brinsupri works by blocking certain inflammatory enzymes in white blood cells, preventing them from becoming overactive and damaging the lungs. Earlier treatments for the condition focused on controlling symptoms by using antibiotics, surgery or devices such as flutter valves to clear the airways. Insmed's application was based on a late-stage trial involving 1,680 adult and 41 adolescent patients, with the drug significantly reducing the frequency of respiratory symptoms such as chronic cough. The drug was found to be safe and well-tolerated at the two tested doses of 10 milligrams and 25 milligrams. TD Cowen analyst Ritu Baral expects the drug to reach peak sales of $3.7 billion in the United States by 2031. Brinsupri has the potential to drive future profitability for the company, she said. Rival treatments in development for the chronic lung condition include AstraZeneca's (AZN.L), opens new tab benralizumab and Zambon's inhaled antibiotic therapy CMS I-neb. This marks the second FDA approval for Insmed following Arikayce, which the agency cleared in 2018 to treat a chronic lung infection caused by bacteria commonly found in soil and water.
Reuters
2 hours ago
- Reuters
US FDA approves Insmed's lung disease drug
Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed's (INSM.O), opens new tab oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. Insmed's drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production. It affects 350,000 to 500,000 adults in the U.S., according to the American Lung Association. Brinsupri works by blocking certain inflammatory enzymes in the white blood cells, preventing them from becoming overactive and damaging the lungs.
Daily Mail
2 hours ago
- Daily Mail
Popular hair growth cream recalled over risk of 'serious injury or death from poisoning'
Officials are raising the alarm over a popular hair loss serum sold nationwide that could cause serious injury and death. Sefralls Minoxidil Hair Generation Serum, sold in amber dropper bottles for $10 on Amazon, is being recalled because it is not in child-resistant packaging. The US Consumer Product Safety Commission, which announced the recall, warned children could accidentally open and consume the minoxidil-laced fluid. Scientists say that consuming just a few ounces of minoxidil, an over-the-counter medication approved by the FDA to reverse hair loss, can cause blood vessels to become dangerously relaxed, triggering extremely low blood pressure. This can cause the heart to shut down, start beating erratically or go into heart failure, and cause death. It can also pose a serious hazard to pets if ingested. About 21,300 units of the product have been recalled and were distributed in the US from June 2024 to June 2025. No injuries or deaths have been reported to date. Guangzhou Ariel Biotech, the Chinese company behind the product, has urged customers to immediately place recalled bottles out of sight or reach of children and contact them for instructions on how to destroy the bottles. It is offering to send replacements to customers who pour the contents of the bottle into the trash, photograph it and send the image to the company. Officials said customers could identify whether their minoxidil had been recalled by whether it mentioned 'Sefralls' and 'minoxidil' on the label. The bottles sold also had a white and gold dropper and a white, black and gold label. The recall is thought to affect every bottle of Sefralls Minoxidil Hair Generation Serum sold in the US. In the recall notice on August 7, the CPSC wrote: 'The hair serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.' All bottles of minoxidil sold in the US are required to be child resistant under the 1970 Poison Prevention Packaging Act. Officials included minoxidil in the act amid mounting concerns over the risk the drug posed to small children. There are no publicly reported fatalities in the US to date among young children who accidentally consumed minoxidil. Minoxidil has exploded in popularity in recent years, alongside hair loss drug finasteride, with about 13million Americans estimated to use the drug in 2024. The US hair loss market has also surged in value, with estimates suggesting it will more than double from a value of $2.84billion to more than $5.26billion over the next decade. The drug works by boosting blood flow to the areas surrounding hair follicles, which can stimulate hair regrowth and restore hair in previously bald patches. It is formulated in low concentrations in hair loss treatments to achieve this effect safely, minimizing the risk to patients. If consumed, doctors treat patients by administering large amounts of fluids and medications to raise blood pressure. The FDA has only approved minoxidil as a drug for treating hair loss. It is at least the second recall over minoxidil being sold in non-child safe bottles in as many months, after another recall was issued in late July for Aemerry Hair Growth Serums, which also was not sold in child-resistant packaging. About 2,300 bottles of the hair growth serums were sold online at from March to June this year for about $22 each. They were sold in black-tinted bottles with droppers for dispensing the serums and navy blue labels with blue and white lettering. The front of the bottles read: 'Aemerry Clinically Proven To Help Regrow Beard 5% Minoxidil with Biotin.' No injuries or deaths have been reported to date, and consumers are being urged to throw out the bottles.
